3396 related articles for article (PubMed ID: 30480766)
1. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
[TBL] [Abstract][Full Text] [Related]
3. Statins for the primary prevention of cardiovascular disease.
Taylor F; Huffman MD; Macedo AF; Moore TH; Burke M; Davey Smith G; Ward K; Ebrahim S
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004816. PubMed ID: 23440795
[TBL] [Abstract][Full Text] [Related]
4. Omega-6 fats for the primary and secondary prevention of cardiovascular disease.
Hooper L; Al-Khudairy L; Abdelhamid AS; Rees K; Brainard JS; Brown TJ; Ajabnoor SM; O'Brien AT; Winstanley LE; Donaldson DH; Song F; Deane KH
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011094. PubMed ID: 30488422
[TBL] [Abstract][Full Text] [Related]
5. Fibrates for primary prevention of cardiovascular disease events.
Jakob T; Nordmann AJ; Schandelmaier S; Ferreira-González I; Briel M
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009753. PubMed ID: 27849333
[TBL] [Abstract][Full Text] [Related]
6. Omega-6 fats for the primary and secondary prevention of cardiovascular disease.
Hooper L; Al-Khudairy L; Abdelhamid AS; Rees K; Brainard JS; Brown TJ; Ajabnoor SM; O'Brien AT; Winstanley LE; Donaldson DH; Song F; Deane KH
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD011094. PubMed ID: 30019765
[TBL] [Abstract][Full Text] [Related]
7. Fibrates for secondary prevention of cardiovascular disease and stroke.
Wang D; Liu B; Tao W; Hao Z; Liu M
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009580. PubMed ID: 26497361
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
9. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
10. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease.
Rees K; Takeda A; Martin N; Ellis L; Wijesekara D; Vepa A; Das A; Hartley L; Stranges S
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009825. PubMed ID: 30864165
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
12. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
13. Niacin for primary and secondary prevention of cardiovascular events.
Schandelmaier S; Briel M; Saccilotto R; Olu KK; Arpagaus A; Hemkens LG; Nordmann AJ
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009744. PubMed ID: 28616955
[TBL] [Abstract][Full Text] [Related]
14. Statins for the primary prevention of cardiovascular disease.
Taylor F; Ward K; Moore TH; Burke M; Davey Smith G; Casas JP; Ebrahim S
Cochrane Database Syst Rev; 2011 Jan; (1):CD004816. PubMed ID: 21249663
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination therapy for the prevention of cardiovascular disease.
de Cates AN; Farr MR; Wright N; Jarvis MC; Rees K; Ebrahim S; Huffman MD
Cochrane Database Syst Rev; 2014 Apr; 4(4):CD009868. PubMed ID: 24737108
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
Bahiru E; de Cates AN; Farr MR; Jarvis MC; Palla M; Rees K; Ebrahim S; Huffman MD
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009868. PubMed ID: 28263370
[TBL] [Abstract][Full Text] [Related]
17. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS; Martin N; Bridges C; Brainard JS; Wang X; Brown TJ; Hanson S; Jimoh OF; Ajabnoor SM; Deane KH; Song F; Hooper L
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012345. PubMed ID: 30484282
[TBL] [Abstract][Full Text] [Related]
18. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS; Martin N; Bridges C; Brainard JS; Wang X; Brown TJ; Hanson S; Jimoh OF; Ajabnoor SM; Deane KH; Song F; Hooper L
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012345. PubMed ID: 30019767
[TBL] [Abstract][Full Text] [Related]
19. Beta-blockers for suspected or diagnosed acute myocardial infarction.
Safi S; Sethi NJ; Nielsen EE; Feinberg J; Jakobsen JC; Gluud C
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012484. PubMed ID: 31845756
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Cochrane Database Syst Rev; ; . PubMed ID: 30521670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
